NO3049208T3 - - Google Patents

Info

Publication number
NO3049208T3
NO3049208T3 NO14741534A NO14741534A NO3049208T3 NO 3049208 T3 NO3049208 T3 NO 3049208T3 NO 14741534 A NO14741534 A NO 14741534A NO 14741534 A NO14741534 A NO 14741534A NO 3049208 T3 NO3049208 T3 NO 3049208T3
Authority
NO
Norway
Application number
NO14741534A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO3049208(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO3049208T3 publication Critical patent/NO3049208T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO14741534A 2012-12-14 2014-06-30 NO3049208T3 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261737276P 2012-12-14 2012-12-14

Publications (1)

Publication Number Publication Date
NO3049208T3 true NO3049208T3 (fr) 2018-04-14

Family

ID=50934967

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14741534A NO3049208T3 (fr) 2012-12-14 2014-06-30

Country Status (12)

Country Link
US (3) US9822347B2 (fr)
EP (2) EP2931265B3 (fr)
JP (2) JP6345690B2 (fr)
AU (3) AU2013359179B2 (fr)
CA (1) CA2894539C (fr)
DK (2) DK3326622T3 (fr)
ES (2) ES2862335T3 (fr)
FI (1) FI2931265T6 (fr)
HK (1) HK1256071A1 (fr)
NO (1) NO3049208T3 (fr)
PT (2) PT3326622T (fr)
WO (1) WO2014093690A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
AU2011207381B2 (en) * 2010-01-22 2016-06-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
EP2931265B3 (fr) 2012-12-14 2023-04-05 The Board of Trustees of the Leland Stanford Junior University Peptides axl modifiés et leur utilisation dans l'inhibition de la signalisation axl dans une thérapie antimétastatique
CA2909669C (fr) 2014-10-20 2023-12-12 Ruga Corporation Activite antivirale de l'inhibiteur gas6
ES2834618T3 (es) * 2014-12-18 2021-06-18 Aravive Biologics Inc Actividad antifibrótica del inhibidor de GAS6
KR20200085307A (ko) * 2017-11-04 2020-07-14 아라바이브 바이올로직스, 인크. Axl 유인 수용체를 이용한 전이성 암의 치료 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0394827A1 (fr) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Polypeptides chimériques de CD4-immunoglobuline
US5538861A (en) 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US20030166109A1 (en) 1997-09-18 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1382969A1 (fr) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnostic et traitement de l'invasion des cellules cancéreuses
WO2004108748A2 (fr) 2002-09-24 2004-12-16 Dow, Kenneth, Centocor, Inc. Peptides du gene 6 specifique de l'arret de croissance, anticorps, compositions, procedes et utilisations associes
AU2004231036A1 (en) 2003-04-18 2004-10-28 Novartis Ag Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis
JP2005278631A (ja) 2004-03-04 2005-10-13 National Institute Of Advanced Industrial & Technology Axlリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法
EP1825005B1 (fr) 2004-11-24 2015-07-15 The Regents of the University of Colorado, a body corporate Agents diagnostiques et therapeutiques a base de mer
CA2607133A1 (fr) 2005-05-02 2006-11-09 Toray Industries, Inc. Composition et procede permettant de diagnostiquer un cancer esophagien et une metastase d'un cancer esophagien
US8168415B2 (en) * 2007-02-07 2012-05-01 The Regents Of The University Of Colorado Axl fusion proteins as Axl tyrosine kinase inhibitors
JP2010523712A (ja) 2007-04-13 2010-07-15 スーパージェン, インコーポレイテッド 癌または過剰増殖の治療に有用なaxlキナーゼ阻害剤
WO2009005813A1 (fr) 2007-07-02 2009-01-08 Wyeth Modulateurs de axl pour le traitement de troubles osseux
US20120230991A1 (en) * 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
EA201100947A1 (ru) * 2008-12-19 2012-02-28 Новартис Аг Растворимые полипептиды, предназначенные для применения при лечении аутоиммунных и воспалительных нарушений
JP5909442B2 (ja) * 2009-05-11 2016-04-26 ユー3・ファーマ・ゲーエムベーハー ヒト化axl抗体
AU2011207381B2 (en) 2010-01-22 2016-06-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
US9074192B2 (en) 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
DK2638173T3 (da) 2010-11-08 2019-09-30 Univ Leland Stanford Junior Fusionsproteiner omfattende et manipuleret knottin-peptid og anvendelser deraf
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
US20150315552A1 (en) 2012-12-14 2015-11-05 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL Signaling in Primary Tumor Therapy
EP2931265B3 (fr) 2012-12-14 2023-04-05 The Board of Trustees of the Leland Stanford Junior University Peptides axl modifiés et leur utilisation dans l'inhibition de la signalisation axl dans une thérapie antimétastatique
WO2015030849A1 (fr) * 2013-08-30 2015-03-05 The Board Of Trustees Of The Leland Stanford Junior University Liaison à haute affinité à gas6
ES2834618T3 (es) * 2014-12-18 2021-06-18 Aravive Biologics Inc Actividad antifibrótica del inhibidor de GAS6

Also Published As

Publication number Publication date
AU2013359179B2 (en) 2017-10-05
JP2018154641A (ja) 2018-10-04
ES2665323T7 (es) 2023-06-15
US20150315553A1 (en) 2015-11-05
PT3326622T (pt) 2021-04-07
AU2019210662B2 (en) 2021-07-01
EP2931265B3 (fr) 2023-04-05
ES2665323T3 (es) 2018-04-25
DK2931265T3 (en) 2018-04-16
EP2931265A1 (fr) 2015-10-21
JP6832887B2 (ja) 2021-02-24
EP2931265A4 (fr) 2016-08-31
WO2014093690A1 (fr) 2014-06-19
US20220220458A1 (en) 2022-07-14
US9822347B2 (en) 2017-11-21
JP2016510309A (ja) 2016-04-07
CA2894539C (fr) 2021-09-28
FI2931265T6 (fi) 2023-05-23
HK1256071A1 (zh) 2019-09-13
PT2931265T (pt) 2018-04-16
ES2862335T3 (es) 2021-10-07
AU2019210662A1 (en) 2019-08-22
US20180030422A1 (en) 2018-02-01
DK2931265T6 (da) 2023-05-01
AU2013359179A1 (en) 2015-07-02
EP2931265B1 (fr) 2018-01-31
CA2894539A1 (fr) 2014-06-19
JP6345690B2 (ja) 2018-06-20
EP3326622B1 (fr) 2021-01-20
US11136563B2 (en) 2021-10-05
AU2017272193A1 (en) 2017-12-21
DK3326622T3 (da) 2021-04-06
EP3326622A1 (fr) 2018-05-30

Similar Documents

Publication Publication Date Title
BR112014017614A2 (fr)
BR112014017592A2 (fr)
BR112014017646A2 (fr)
BR112014018648A2 (fr)
AR092201A1 (fr)
BR112014017607A2 (fr)
BR112013027865A2 (fr)
BR112014017609A2 (fr)
BR112014017647A2 (fr)
BR112014017588A2 (fr)
BR112014017618A2 (fr)
BR112014013184A8 (fr)
BR112014017630A2 (fr)
BR112014017652A2 (fr)
BR112014017621A2 (fr)
BR112014017622A2 (fr)
BR112014017627A2 (fr)
BR112014017623A2 (fr)
BR112014017631A2 (fr)
NO3049208T3 (fr)
BR112014017600A2 (fr)
BR112014017671A2 (fr)
BR112014017948A2 (fr)
BR112014017596A2 (fr)
BR112014017591A2 (fr)